... Capivasertib (Truqap) is an AKT inhibitor. Inavolisib (Itovebi) and Alpelisib (Piqray) are PI3K inhibitors.PARP InhibitorsPoly (ADP-ribose) polymerase (PARP) is a protein found in cells that helps damaged cells repair themselves. ...
... This means that fulvestrant helped people live longer with stable disease compared to anastrozole.New Therapies for Advanced HR-Positive Breast CancerCapivasertib combined with fulvestrant (Truqap) was approved for HR-positive, HER2-negative breast cancer in 2023. Capivasertib is a serine/threonine kinase inhibitor. ...
New Treatments for Metastatic Breast Cancer: Extending Life
... This means that fulvestrant helped people live longer with stable disease compared to anastrozole.New Therapies for Advanced HR-Positive Breast CancerCapivasertib combined with fulvestrant (Truqap) was approved for HR-positive, HER2-negative breast cancer in 2023. Capivasertib is a serine/threonine kinase inhibitor. ...